Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Controlling the complement system in inflammation

M Kirschfink1

  • 1Institute of Immunology, University of Heidelberg, Germany. k92@ix.urz.uni-heidelberg.de

Immunopharmacology
|February 26, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Local complement activation in aqueous humor in patients with age-related macular degeneration.

Eye (London, England)·2017
Same author

Monitoring of complement activation biomarkers and eculizumab in complement-mediated renal disorders.

Clinical and experimental immunology·2016
Same author

Dissection of CD20 regulation in lymphoma using RNAi.

Leukemia·2016
Same author

Tailored eculizumab regimen for patients with atypical hemolytic uremic syndrome: requirement for comprehensive complement analysis.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Complement profile in neonates of different gestational ages.

Scandinavian journal of immunology·2014
Same author

Pulp progenitor cell recruitment is selectively guided by a C5a gradient.

Journal of dental research·2013

Therapeutic inhibition of the complement system can reduce inflammatory tissue damage in various diseases. Strategies include using inhibitors, antibodies, and complement regulators to control inflammation and prevent organ failure.

Area of Science:

  • Immunology
  • Inflammation research
  • Therapeutic strategies

Background:

  • Excessive complement system activation causes severe inflammatory tissue destruction, leading to conditions like septic shock and organ failure.
  • Genetic complement deficiencies reduce tissue injury in animal models, suggesting therapeutic complement inhibition is beneficial.
  • Controlling complement activation is crucial for managing inflammatory disorders and preventing multiple organ dysfunction syndrome.

Purpose of the Study:

  • To review current strategies for therapeutic complement inhibition in inflammation.
  • To provide an overview of state-of-the-art methods to prevent multiple organ failure following systemic inflammatory response.
  • To discuss the clinical relevance and diagnostic developments in complement activation.

Main Methods:

Related Experiment Videos

  • Application of endogenous soluble complement inhibitors (e.g., C1-inhibitor, rsCR1).
  • Administration of antibodies targeting complement proteins (C3, C5) or anaphylatoxin C5a.
  • Interference with complement receptor 3 (CR3)-mediated cell adhesion.
  • Incorporation of membrane-bound complement regulators (DAF, MCP, CD59) into cells.

Main Results:

  • Complement inhibition strategies have shown protective effects in animal models of sepsis, ischemia/reperfusion injury, and graft rejection.
  • Clinical trials indicate that complement inhibition is a viable therapeutic approach for controlling inflammation.
  • Various methods, including inhibitors and antibodies, are being explored to specifically target complement in inflammatory conditions.

Conclusions:

  • Therapeutic complement inhibition shows promise for treating inflammatory diseases and preventing organ damage.
  • Further research and clinical application of complement-directed therapies are warranted.
  • Controlling complement activation is a key target for managing systemic inflammation and its severe consequences.